Youll meet face-to-face with one of our experienced medical providers to go over your medical profile, symptoms, and more
Since its launch in 2017, the JDC1 has fast become an industry standard
This effect underscores the importance of blood sugar monitoring in extended cycles
To view or add a comment, sign in Practice-Changing Update in Obesity Care (April 2026) The orforglipron (Foundayo) has received FDA approvalmarking a major milestone as the first oral, non-peptide GLP-1 receptor agonist
If you have significant eye disease, a conservative dosing approach may reduce your risk while still providing benefits
Medication Selection : Based on your individual needs, our doctor recommends whether semaglutide , tirzepatide , or another GLP-1 medication is best suited for your situation